Pediatric Allergy and Immunology, Mount Sinai School of Medicine, New York, NY 10029, USA.
J Allergy Clin Immunol. 2012 May;129(5):1321-1328.e5. doi: 10.1016/j.jaci.2012.02.012. Epub 2012 Mar 23.
Peanut allergy is relatively common, typically permanent, and often severe. Double-blind, placebo-controlled food challenge is considered the gold standard for the diagnosis of food allergy-related disorders. However, the complexity and potential of double-blind, placebo-controlled food challenge to cause life-threatening allergic reactions affects its clinical application. A laboratory test that could accurately diagnose symptomatic peanut allergy would greatly facilitate clinical practice.
We sought to develop an allergy diagnostic method that could correctly predict symptomatic peanut allergy by using peptide microarray immunoassays and bioinformatic methods.
Microarray immunoassays were performed by using the sera from 62 patients (31 with symptomatic peanut allergy and 31 who had outgrown their peanut allergy or were sensitized but were clinically tolerant to peanut). Specific IgE and IgG(4) binding to 419 overlapping peptides (15 mers, 3 offset) covering the amino acid sequences of Ara h 1, Ara h 2, and Ara h 3 were measured by using a peptide microarray immunoassay. Bioinformatic methods were applied for data analysis.
Individuals with peanut allergy showed significantly greater IgE binding and broader epitope diversity than did peanut-tolerant individuals. No significant difference in IgG(4) binding was found between groups. By using machine learning methods, 4 peptide biomarkers were identified and prediction models that can predict the outcome of double-blind, placebo-controlled food challenges with high accuracy were developed by using a combination of the biomarkers.
In this study, we developed a novel diagnostic approach that can predict peanut allergy with high accuracy by combining the results of a peptide microarray immunoassay and bioinformatic methods. Further studies are needed to validate the efficacy of this assay in clinical practice.
花生过敏相对常见,通常为永久性,且往往较为严重。双盲、安慰剂对照食物挑战被认为是诊断食物过敏相关疾病的金标准。然而,双盲、安慰剂对照食物挑战的复杂性和潜在的致命过敏反应影响了其临床应用。一种能够准确诊断有症状花生过敏的实验室检测方法将极大地促进临床实践。
我们试图通过肽微阵列免疫分析和生物信息学方法开发一种能够正确预测有症状花生过敏的过敏诊断方法。
通过使用来自 62 名患者(31 名有症状花生过敏,31 名已消除花生过敏或致敏但临床耐受花生)的血清进行微阵列免疫分析。使用肽微阵列免疫分析测量针对 Ara h 1、Ara h 2 和 Ara h 3 氨基酸序列的 419 个重叠肽(15 个氨基酸,3 个偏移)的特异性 IgE 和 IgG(4)结合。应用生物信息学方法进行数据分析。
花生过敏个体的 IgE 结合显著高于花生耐受个体,且表位多样性更广。两组间 IgG(4)结合无显著差异。通过使用机器学习方法,确定了 4 个肽生物标志物,并通过结合这些生物标志物开发了可以准确预测双盲、安慰剂对照食物挑战结果的预测模型。
在这项研究中,我们开发了一种新的诊断方法,通过结合肽微阵列免疫分析和生物信息学方法,可以高度准确地预测花生过敏。需要进一步的研究来验证该检测方法在临床实践中的疗效。